SCHULMAN AMY W 4

What Happened

• Amy W. Schulman, a director of Alnylam Pharmaceuticals (ALNY), was granted awards on 2026-05-20: 838 restricted stock units (RSUs) and a derivative award covering 1,802 shares. Both grants show $0 acquisition price (i.e., compensation awards), totaling 2,640 shares on paper and $0 cash paid.
• These are awards (compensation), not open-market purchases or sales.

Key Details

• Transaction date: 2026-05-20; Filing date: 2026-05-22 (filed timely under the Form 4 two-business-day rule).
• Price: $0.00 per share — these are compensation grants, not cash purchases.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes / vesting notes:
  • The 838 shares are RSUs; each RSU converts to one share. RSUs vest in full on the earlier of the first anniversary of the grant or earlier retirement/resignation, provided such retirement/resignation occurs no more than 90 days before the first anniversary.
  • The 1,802-share derivative award is subject to a similar vesting condition (it will vest in full on the earlier of the first anniversary of the grant or certain earlier retirement/resignation timing).

Context

• Grants like RSUs or option awards are standard director compensation and do not necessarily indicate buying or selling sentiment. They generally vest over time or upon specified conditions; they are not immediate cash purchases or sales.
• The derivative award should be understood as a future right to obtain shares (subject to vesting), not an immediate share transfer.